No Data
Sinolink: Pharmaceutical sector under pressure in the early stage, reversal in 2025 comes from three major opportunities.
With the continuous aging of the population, stable expansion of residents' medical consumption, and the continuous recovery of industry diagnosis and treatment volume, the long-term growth logic of the medical industry remains clear, and the overall foundation is stable.
Humanwell Healthcare Secures Clinical Trial Approval for Yucan Granules
Humanwell Healthcare (600079.SH): Yucan particles obtained approval for clinical trials of drugs.
humanwell healthcare (600079.SH) announced that its wholly-owned subsidiary, wuhan humanwell innovative drugs research and development center limited...
Humanwell Healthcare (600079.SH): Chairman Li Jie has cumulatively reduced his shareholding by 0.66% of the company's shares.
As of the date of this announcement, humanwell healthcare (600079.SH) disclosed that the shareholding plan has reached the end of the shareholding period, and Chairman Li Jie has cumulatively reduced the company's shares by 10,732,900 shares, accounting for 0.66% of the total share capital of the company.
Open Source Securities' investment strategy for the pharmaceutical industry in 2025: The long-term industry trend has not changed, focusing on the sector stabilizing and rebounding.
At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, and the continuous improvement of enterprise innovation capabilities are long-term industry trends that have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance income suppressing the pharmaceutical sector will gradually improve.
We Think Humanwell Healthcare (Group)Ltd (SHSE:600079) Can Stay On Top Of Its Debt
The Market Doesn't Like What It Sees From Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings YetNo Data
No Data
